Aminoglycosides, recommended by the World Health Organization to treat multidrug resistant tuberculosis, cause hearing loss and kidney damage in a dose dependent manner. Now, by reducing the dose in a carefully calculated fashion, clinician researchers have been able to greatly reduce the numbers of patients suffering hearing loss, without compromising effectiveness against tuberculosis.